Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study

Liver International

Volumn 35, Issue 1, 2015, Pages 79-89

  Gane, Edward J ^a   Pockros, Paul J ^b   Zeuzem, Stefan ^c   Marcellin, Patrick ^d   Shikhman, Anna ^e   Bernaards, Coen ^f   Zhou, Julian ^g   Yetzer, Ellen S ^f   Ballester, Rosa ^h   Dwyer, Cindy ^e   Tong, Xiao ^e   Nájera, Isabel ^e   Bertasso, Anne ^e   Hammond, Janet ^e   Kindrick, Amy ^f   Morcos, Peter N ^e   Smith, Patrick ^e,i   Stancic, Saray ^e   Shulman, Nancy S ^f,j  

^a Auckland Clinical Studies   (New Zealand)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d BEAUJON HOSPITAL   (France)

^e HOFFMANN LA ROCHE INC   (United States)

^f GENENTECH INC   (United States)

^g Roche Product Development in Asia Pacific   (China)

^h ROCHE PRODUCTS LTD   (United Kingdom)

ⁱ D3 Medicine LLC   (United States)

^j ABBVIE INC   (United States)

more..

Author keywords

Chronic hepatitis C; Danoprevir; Direct acting antiviral; Interferon free; Mericitabine; Response guided; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DANOPREVIR; HEMOGLOBIN; MERICITABINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PHOSPHATE; PLACEBO; RIBAVIRIN; RITONAVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VIRUS RNA; 2'-FLUORO-2'-METHYL-3',5'-DIISOBUTYRYLDEOXYCYTIDINE; DEOXYCYTIDINE; LACTAM; SULFONAMIDE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS MUTATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ELECTROCARDIOGRAPHY; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED;

ADULT; AGED; DEOXYCYTIDINE; ELECTROCARDIOGRAPHY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LACTAMS; MALE; MIDDLE AGED; RIBAVIRIN; RITONAVIR; RNA, VIRAL; SULFONAMIDES;

EID: 84921028832     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12588     Document Type: Article

References (42)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
2. US Food and Drug Administration (FDA). Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. 6 December 2013. Available at http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htm. Accessed January 2014.
3. US Food and Drug Administration (FDA). FDA approves new treatment for hepatitis C virus. 22 November 2013. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm376449.htm. Accessed January 2014.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
6. Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 2004; 3: 5-10.
7. Manns M, Marcellin P, Fred Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S568. Abstract 1413.
8. Jacobson I, Dore G J, Foster G R, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S574. Abstract 1425.
9. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
10. Leveque V, Fung A, Le Pogam S. Nucleoside analog R7128, a prodrug of PSI-6130, shows inhibition potency across HCV genotypes 1-6 in vitro. 16th International Symposium on Hepatitis C Virus and Related Viruses, Nice, France; 2009. Poster P-215.
11. Reddy K R, Rodriguez-Torres M, Gane E J, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007; 46: LB9.
12. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008; 52: 4356-69.
13. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141: 1067-79.
14. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011; 53: 1090-9.
15. Everson G, Cooper C, Hezode C, et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/Peg-IFNa-2a/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis. J Hepatol 2012; 56: S466. Abstract 1177.
16. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 972-9.
17. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-75.
18. Zeuzem S, Asselah T, Angus P, et al. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther 2013; 18: 1015-9.
19. Di Bisceglie A M, Nelson D R, Gane E, et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: ZENITH study interim results. J Hepatol 2011; 54(Suppl. 1): S540. Abstract 1363.
20. Jacobson I, Sulkowski M, Gane E, et al. VX-222, telaprevir, and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen. Hepatology 2013; 56(Suppl.): 308A.
21. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.
22. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
23. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
24. Sarrazin C, Lim S, Qin X, et al. Kinetic analysis of viral rebound and drug-resistant viral variant dynamics in patients treated with ITMN-191 (R7227) monotherapy suggests a high barrier to viral escape. Hepatology 2009; 50: 953A.
25. Pockros PJ, Jensen D, Tsai N, et al. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58: 514-23.
26. Wedemeyer H, Jensen D, Herring R Jr, et al. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58: 524-37.
27. Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-9.
28. Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014; 209: 668-75.
29. Le Pogam S, Yan J, Kosaka A, et al. No evidence of drug resistance or baseline S282T resistance mutation among GT 1 and GT 4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study. Hepatology 2010; 52: 701A-2A.
30. Wedemeyer H, Jensen D, Herring R, et al. Efficacy and safety of mericitabine (MCB) in combination with Peg-IFNa-2a/RBV in G1/4 treatment naive HCV patients: final analysis from the PROPEL study. J Hepatol 2012; 56: S481. Abstract 1213.
31. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
32. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral QUAD regimen: interim results. J Hepatol 2012; 56: S560. Abstract 1421.
33. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
34. Asselah T. ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. J Hepatol 2013; 59: 885-8.
35. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; doi: 10.1002/hep.27113. [Epub ahead of print].
36. Guedj J, Dahari H, Shudo E, et al. viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012; 55: 1030-7.
37. Jensen D M, Brunda M, Elston R, et al. Interferon-free regimen containing setrobuvir in combination with ritonavir-boosted danoprevir and ribavirin with or without mericitabine in HCV genotype 1 treatment-naive patients: interim results from the ANNAPURNA study. Hepatology 2013; 58 (Suppl.): 741A.
38. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
39. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and Is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
40. Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790-5.
41. Terrault N, Cooper C, Balart LA, et al. Phase II randomised, partially-blind, parallel-group study of oral danoprevir (RG7227) with PegIFN-2a (PEGASYS{reversed not sign}) plus ribavirin in treatment-naive genotype 1 patients with CHC: results of planned Week 12 interim analysis of the ATLAS study. Hepatology 2010; 52: 73A.
42. Goelzer P, Morcos PN, Tran JQ, et al. Ritonavir substantially reduces reactive metabolite formation of the HCV protease inhibitor danoprevir both in vitro and in vivo. J Hepatol 2012; 56: S467. Abstract 1180.